These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 21395432)
1. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology. Geller DE; Weers J; Heuerding S J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):175-82. PubMed ID: 21395432 [TBL] [Abstract][Full Text] [Related]
2. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis. Somayaji R; Parkins MD Ther Deliv; 2015 Feb; 6(2):121-37. PubMed ID: 25690082 [TBL] [Abstract][Full Text] [Related]
3. Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. McKeage K Drugs; 2013 Nov; 73(16):1815-27. PubMed ID: 24194436 [TBL] [Abstract][Full Text] [Related]
4. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062 [TBL] [Abstract][Full Text] [Related]
5. The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis. Tappenden P; Harnan S; Uttley L; Mildred M; Walshaw M; Taylor C; Brownlee K Pharmacoeconomics; 2014 Feb; 32(2):159-72. PubMed ID: 24338264 [TBL] [Abstract][Full Text] [Related]
6. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Konstan MW; Geller DE; Minić P; Brockhaus F; Zhang J; Angyalosi G Pediatr Pulmonol; 2011 Mar; 46(3):230-8. PubMed ID: 20963831 [TBL] [Abstract][Full Text] [Related]
7. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients]. Pierart F Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205 [TBL] [Abstract][Full Text] [Related]
8. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study. Blasi F; Carnovale V; Cimino G; Lucidi V; Salvatore D; Messore B; Bartezaghi M; Muscianisi E; Porpiglia PA; Respir Med; 2018 May; 138():88-94. PubMed ID: 29724399 [TBL] [Abstract][Full Text] [Related]
9. Eradication of Akkerman-Nijland AM; Yousofi M; Rottier BL; Van der Vaart H; Burgerhof JGM; Frijlink HW; Touw DJ; Koppelman GH; Akkerman OW Ther Adv Respir Dis; 2020; 14():1753466620905279. PubMed ID: 32046620 [TBL] [Abstract][Full Text] [Related]
10. Use of inhaled tobramycin in cystic fibrosis. Shteinberg M; Elborn JS Adv Ther; 2015 Jan; 32(1):1-9. PubMed ID: 25620537 [TBL] [Abstract][Full Text] [Related]
11. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis. Vazquez-Espinosa E; Marcos C; Alonso T; Giron RM; Gomez-Punter RM; Garcia-Castillo E; Zamora E; Cisneros C; Garcia J; Valenzuela C; Ancochea J Expert Rev Anti Infect Ther; 2016; 14(1):9-17. PubMed ID: 26559549 [TBL] [Abstract][Full Text] [Related]
12. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Parkins MD; Elborn JS Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231 [TBL] [Abstract][Full Text] [Related]
13. Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence. Hamed K; Debonnett L Ther Adv Respir Dis; 2017 May; 11(5):193-209. PubMed ID: 28470103 [TBL] [Abstract][Full Text] [Related]